The NICE press team issues press releases on all published Clinical Guidelines, Technology Appraisals, and Public Health guidance, as well as for consultations on draft guidance and other news from NICE. Press releases are usually issued under embargo on the day before they are published on the website. If you are a journalist and would like to be added to our mailing list, please send an email to pressoffice@nice.org.uk or call the press team on 0845 003 7782.
|
|
An integrated approach to asthma services is vital, says NICE in new quality standard
NICE has today (21 February) published a new quality standard on the diagnosis and treatment of asthma in adults, young people and children aged 12 months and older.
February 21, 2013
|
|
Updated NICE guidelines revise treatment recommendations for people with fertility problems
People who are experiencing fertility problems should be able to get the most appropriate and effective medical treatment earlier, thanks to new updated guidelines published today (Wednesday 20 February) by the National Institute for Health and Clinical Excellence (NICE).
February 20, 2013
|
|
Draft NICE guidance recommends new test to guide breast cancer treatment decisions
Draft guidance from NICE?s Diagnostics Assessment Programme on four tests used to guide decisions about the use of chemotherapy in people with early breast cancer recommends the use of Oncotype DX for people who are assessed as being at intermediate risk to guide chemotherapy decisions where the manufacturer provides it at the price offered through the confidential access proposal.
February 18, 2013
|
|
New accreditations from NICE
The National Institute for Health and Clinical Excellence (NICE) has today (14 February 2013) accredited The British Society for Allergy and Clinical Immunology (BSACI) for its processes to produce BSACI guidelines and the College of Occupational Therapists (COT) for its processes to produce Practice Guidelines.
February 15, 2013
|
|
NICE consults on preliminary recommendations for a new treatment for enlarged spleen in adults with myelofibrosis.
NICE has today (13 February) issued new draft guidance not recommending ruxolitinib (Jakavi, Novartis), for the treatment of disease-related splenomegaly (enlarged spleen) or symptoms in adults with primary myelofibrosis, or myelofibrosis secondary to polycythaemia vera or essential thrombocythaemia.
February 13, 2013
|
|
NICE consults on recommendations for treating people with acute heart attack
NICE is currently developing a clinical guideline on the acute management of myocardial infarction (heart attack) with ST-segment-elevation (STEMI). Today (8 February), and has issued a draft version of the guideline for public consultation.
February 8, 2013
|
|
NICE consults on updated treatment advice for millions of women suffering from urinary incontinence
The National Institute for Health and Clinical Excellence (NICE) is currently updating its clinical guideline for the management of urinary incontinence (UI). The update aims to provide healthcare practitioners with up-to-date advice on available treatment options for women who are affected by this condition and a draft version of this updated guideline has today (5 February) been published for public consultation.
February 5, 2013
|
|
Consultation opens on 2014/15 Clinical Commissioning Group Outcomes Indicator Set
NICE has today opened its consultation on potential additional indicators for the proposed 2014/2015 Clinical Commissioning Group Outcomes Indicator Set (CCGOIS, formerly known as the 'Commissioning Outcomes Framework').
February 1, 2013
|
|
NICE consultation opens on drug for severe gout
The National Institute for Health and Clinical Excellence (NICE) has today (Friday 1 February 2013) opened a consultation on a drug for severe gout.
February 1, 2013
|
|
NICE draft guidance does not recommend bevacizumab for recurrent advanced ovarian cancer
The National Institute for Health and Clinical Excellence (NICE) has published draft guidance today (1 February) on the use of bevacizumab (Avastin, Roche) for treating advanced ovarian cancer that has returned six months or more after initial treatment with platinum-based chemotherapy (platinum-sensitive disease).
February 1, 2013
|
This page was last updated: 14 June 2013